We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Frontier Ip Group Plc | LSE:FIPP | London | Ordinary Share | GB00B63PS212 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 29.00 | 28.00 | 30.00 | 29.00 | 29.00 | 29.00 | 50,172 | 07:36:30 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Real Estate Agents & Mgrs | 358k | -1.13M | -0.0163 | -17.79 | 19.98M |
From Jan 2020 to Jan 2025
TIDMFIPP
RNS Number : 0988U
Frontier IP Group plc
27 March 2019
27 March 2019
Frontier IP Group Plc
("Frontier IP" or the "Group")
UNAUDITED HALF YEAR RESULTS FOR THE SIX MONTHS TO 31 DECEMBER 2018
Frontier IP, a specialist in commercialising university intellectual property, is pleased to announce its interim results for the six month period ended 31 December 2018.
KEY POINTS:
The Group enjoyed a very strong first half to the year. Three new spin outs were incorporated, including the first two in Portugal, and four portfolio companies announced collaboration agreements with major industry partners. These agreements represent significant steps towards proving the commercial viability of their technology. Further validation came from the success of portfolio companies in winning public sector and private sector funding support.
The fair value of the portfolio rose by 27 per cent. to GBP11.5 million at 31 December 2018 (30 June 2018: GBP9.1 million). Total revenues rose by 83 per cent. to GBP2.2 million (2017: GBP1.2 million) and pre-tax profits by 138 per cent. to GBP1.2 million (2017: GBP0.5 million). A successful placing raised GBP2.3 million (net of expenses) for the Group in November 2018.
FINANCIAL HIGHLIGHTS:
-- Fair value of the portfolio increased by 27 per cent. to GBP11,508,000 at 31 December 2018 (30 June 2018: GBP9,060,000), an increase of 43 per cent. year on year (31 December 2017: GBP8,020,000)
-- Total revenue increased 83 per cent. to GBP2,176,000 (2017: GBP1,188,000) - the increase reflecting a higher gain on the revaluation of investments of GBP1,983,000 (2017: GBP1,068,000)
-- Revenue from services increased 61 per cent. to GBP193,000 (2017: GBP120,000)
-- Profit before tax increased 138 per cent. to GBP1,247,000 (2017: GBP524,000) - the increase reflecting the higher gain on revaluation of investments and accounting for greater administrative costs, which rose to GBP939,000 (2017: GBP667,000)
-- Basic earnings per share increased by 172 per cent.to 3.18p (2017: 1.17p)
-- Net assets per share increased to 38.8p as at 31 December 2018 (30 June 2018: 33.2p; 31 December 2017: 32.0p)
-- Cash balances stood at GBP2,528,000 as at 31 December 2018 (30 June 2018: GBP1,111,000; 31 December 2017: GBP1,849,000) following a placing in November 2018 which raised GBP2,333,000 (net of expenses)
PORFOLIO AND OPERATIONAL HIGHLIGHTS:
The six months to 31 December 2018 saw highly encouraging commercial progress with momentum continuing strongly after the period end.
-- Tarsis Technology, Fieldwork Robotics, Molendotech and new University of Plymouth spin-out Amprologix announced collaboration agreements with major industry partners. Further details below
-- Full commercial launch of the Siren(BW) bathing water test kit, based on Molendotech's IP, by Palintest, a subsidiary of FTSE 100 group Halma
-- First spin outs in Portugal, NTPE and Des Solutio, from NOVA University Lisbon - NOVA School of Science and Technology
-- Alusid raised GBP1.34 million to support planning for manufacturing scale up
-- Government-backed grants awarded to Pulsiv Solar and The Vaccine Group to accelerate technology development
-- Oversubscribed placing for Frontier IP raised GBP2.33 million (net of expenses) for the Group from existing and new investors
-- Former AB Sugar Head of Innovation Matthew White joined as Director of Commercialisation -- Strategic partnership with UK Department for International Trade in Portugal -- Post period end:
o Exscientia signed AI drug discovery collaboration agreement with Celgene Corporation, which included initial payment of US$25 million. Exscientia has also raised US$26 million in a Series B funding round and signed Roche collaboration agreement worth up to CHF 67 million
o The US Defense Advanced Research Project Agency named The Vaccine Group as an integral part of $9.67 million project to combat Ebola, Lassa fever and other deadly viruses. TVG also won Department of Health and Social Care grant as part of Anglo-Chinese project
o UK government funding from Department of Health and Social Care to Amprologix and Innovate UK to Nandi Proteins
o Third Portuguese spin out, Insignals Neurotech, from the Institute for Systems and Computer Engineering, Technology and Science
o Director of Commercialisation Matthew White joined the board as an executive director, as separately announced today
Chief Executive Neil Crabb said: "Our business model is based on proving the commercial value of intellectual property by working closely with universities, academics and industry. Only when we are confident the technology works, can be scaled up, and meets a market need or demand, will we ask investors to make significant commitments to the portfolio companies.
The first half of the year provides further evidence our approach is gaining traction with stakeholders.
Four companies announced collaboration agreements with industrial partners, all of whom are among the leaders in their respective sectors.
Three new spin outs joined our portfolio, including the first two in Portugal, a market where we aim to be the market leader. Palintest, a subsidiary of FTSE 100 Group Halma, has started the commercial roll out of bathing water testing kit Siren(BW) , based on Molendotech's IP, while Alusid gained strong support for its GBP1.34 million fund raising to support planning for manufacturing scale up.
We are mindful of the risks in the Group. The nature of the early and development stage companies in our portfolio means their rate of progress or eventual success cannot always be assured.
However, these are strong results. We have generated momentum on all fronts - new spin outs, industry partnerships, and raising funds from private and public sector sources - during the first half. The momentum has gathered pace into the second half of the year. That's why, based on trading for the year to date and what we see coming down the line, we anticipate that the outcome for the full financial year, ending 30 June 2019, will be ahead of management expectations."
ENQUIRIES
Frontier IP Group Plc T: 0131 240 1251 Neil Crabb, Chief Executive Officer Andrew Johnson, Communications & Investor M: 07464 546 025 Relations Allenby Capital Limited (Nominated Adviser T: 0203 328 5656 and Broker) Nick Athanas Nicholas Chambers
ABOUT FRONTIER IP: www.frontierip.co.uk
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
Interim Management Statement
Summary
Frontier IP made good progress in pursuing growth and value for shareholders by:
-- Identifying IP with strong commercial potential to build portfolio - three new spin outs incorporated including first two from Portugal
-- Developing industry partnerships to validate technology and scale up: four collaboration agreements announced in the half year
-- Supporting fund raising for further development - GBP1.34 million raised for Alusid, government-backed funding for The Vaccine Group and Pulsiv Solar
-- Generating strong financial results: fair value of portfolio increased by 27 per cent. to GBP11.5 million, total revenues by 83 per cent. to GBP2.2 million, and pre-tax profits by 138 per cent. to GBP1.2 million. Cash balances at period end of GBP2.53 million after oversubscribed placing of GBP2.33 million (net of expenses)
Operational Review
There were positive developments for the Group and its portfolio companies during the half year to December 31, 2018. We continued to build our portfolio, further developed our relationships with university, government and industry partners, and strengthened our team.
Portfolio developments
We added three new spin outs to our portfolio during the period, including the first two in Portugal, and one more from the University of Plymouth. Our other portfolio companies enjoyed solid progress, including several new industry partnerships agreed. Tarsis Technology is collaborating with a world-leading crop protection group, Fieldwork Robotics is developing a soft-fruit harvester with Hall Hunter Partnership, Molendotech is working with G's Fresh, one of Europe's biggest fresh produce groups, and Amprologix with industrial biotechnology group Ingenza.
The new spin outs were:
NTPE: Frontier IP stake 31.6 per cent
NTPE, a spin out from Portugal's NOVA University Lisbon, NOVA School of Science and Technology ("FCT NOVA"), is developing novel technology, called Paper-E, to print electronic circuits, sensors and semiconductors onto any cellulose-based paper. The technology is being developed by a team of over 65 researchers under the leadership of Professors Elvira Fortunato and Rodrigo Martins. Potential applications include paper-based biosensors for diagnostics, smart packaging, and for use in fraud prevention. NTPE was the Group's first spin out in Portugal.
Des Solutio: Frontier IP stake 25 per cent
Another FCT NOVA spin out, Des Solutio is developing safer and greener alternatives to the chemicals currently used to make beauty, pharmaceutical, personal care and other products. The technology has already attracted interest from several industrial groups. It is being developed by Associate Professor Ana Rita Duarte and Dr Alexandre Paiva.
Amprologix: Frontier IP stake 10 per cent
University of Plymouth spin out Amprologix is developing new classes of antibiotics to combat MRSA and other superbugs. Scale up is already being supported through a partnership with biotechnology and synthetic biology company Ingenza. IBM Watson and the National Physical Laboratory are working with Amprologix to improve antibiotic properties. Post period end, the company won GBP1.2 million funding from the Department of Health and Social Care to accelerate development of its lead compound, Epidermicin NI01.
Other portfolio developments included:
Exscientia: Frontier IP stake 3.32 per cent
Exscientia, a leader in using artificial intelligence in drug discovery, acquired fellow portfolio company Kinetic, a biophysics specialist, to build its capabilities for tackling novel drug targets to create first-in-class drug candidates. Post period end, the company raised US$26 million in a Series B funding round and announced two AI drug discovery collaboration agreements. The first with Roche is worth up to CHF 67 million. The second with Celgene Corporation included an initial payment of US$25 million and eligibility to receive substantial milestone payments and tiered royalties on net sales of any products resulting from the collaboration.
Molendotech: Frontier IP stake 14.1 per cent
Palintest, a subsidiary of FTSE 100 group Halma, started commercial roll out of Siren(BW) a rapid water testing kit based on Moldendotech's novel technology to detect bacteria in water. The University of Plymouth spin out also signed a collaboration agreement to develop water tests for G's Group, one of Europe's leading fresh produce companies.
Alusid: Frontier IP stake 35.6 per cent
University of Central Lancashire spin out Alusid uses a patented process to make high-quality tiles and surfaces by recycling industrial waste ceramics and glass otherwise destined for landfill. The company raised GBP1.34 million through a private funding round to support the planning for manufacturing scale up. It also won the prestigious Jonathan Hindle Prize for outstanding design in 2D materials, awarded by The Furniture Makers' Company.
Fieldwork Robotics: Frontier IP stake 27.5 per cent
Fieldwork Robotics from the University of Plymouth entered into a collaboration agreement with one of the UK's biggest soft-fruit growers Hall Hunter Partnership to prototype and field test a raspberry harvesting robot system. The agreement will enable Fieldwork to test and further refine the technology by working in a range of environments.
Pulsiv Solar: Frontier IP stake 18.9 per cent
Pulsiv Solar, which develops novel technology to improve the energy efficiency of photovoltaic cells and power converters, won a GBP129,929 grant from Innovate UK towards a GBP288,732 project to complete technological development of its solar micro-inverter. The project is creating a product ready for scale up and commercialisation offering energy efficiency improvements of at least 5 per cent over current market leaders. Other applications being explored for the technology include improving the energy efficiency of power converters used in a huge range of consumer devices, such as televisions, mobile phones and laptops.
Tarsis Technology: Frontier IP stake 18 per cent
University of Cambridge spin out Tarsis Technology entered into a collaboration agreement with one of the world's leading manufacturers of crop-protection products. The collaboration is researching the use of Tarsis' metal-organic-framework technology to deliver pesticides and fungicides in a more precise and controlled way. The technology has a wide range of potential applications.
As previously announced Frontier IP agreed to lend up to GBP150,000 to Tarsis to enable the company to meet its working capital requirements in return for equity options- this is an example of Frontier IP's efficient capital model in action. As at 31 December 2018 Frontier IP have under this arrangement provided a loan totaling GBP40,000 to Tarsis.
The Vaccine Group: Frontier IP stake 19.2 per cent
The Vaccine Group's novel technology has the potential to be used as a base for many different vaccines to combat diseases, such as Ebola and Lassa fever, that can jump from animals to animals or humans. The company won a GBP50,000 grant from global bacteriology network Bactivac to develop a vaccine to tackle one of the main causes of bovine mastitis, E.coli. Post period end, the company won a GBP403,000 grant from the Department of Health and Social Care as part of a GBP1.46 million Anglo-Chinese project to combat S.suis in pigs, a disease which can cause meningitis in humans. After the period end, the company was named as an integral partner in a US$9.67 million US DARPA project to protect the US military forces and homeland from zoonotic diseases.
Further post period end portfolio developments:
Nandi Proteins: Frontier IP stake 20.7 per cent
Nandi Proteins is developing novel ingredients to replace sugar, fat and E-number additives in food. The company won a GBP180,697 grant from Coeliac UK and Innovate UK, the UK's innovation agency, as part of a GBP250,000 project to create new ingredients to improve the taste and texture of gluten-free bread. Nandi is leading the project, in which the other commercial partners are Genius Foods, Agrii, part of Origin Enterprises plc, and AB Mauri, the ingredients subsidiary of FTSE 100 group AB Foods.
Insignals Neurotech: Frontier IP stake 33 per cent
We incorporated our third Portuguese spin out after the period end. Insignals Neurotech is a spin out from the Institute for Systems and Computer Engineering, Technology and Science, with the support of São João University Hospital, part of the University of Porto. The company is developing wireless wearable devices to aid deep brain surgery on patients suffering from Parkinson's disease and other neurological conditions.
Corporate developments
The Group continued to make significant progress during the first half of the year to provide the basis for future growth and value creation.
We strengthened our team with the appointment of Matthew White as Director of Commercialisation. Matt's immediate role before joining was Head of Innovation for AB Sugar. He has more than 23 years' experience in technology, product and service innovation, business development and marketing. He is based in our Cambridge office. Matt has now been appointed to the board as an executive director, further details of which have been announced today.
The Group also built on its growing position in Portugal by signing a partnership agreement with the UK government's Department for International Trade. The move means the British Embassy in Lisbon is providing strategic support for Frontier IP, including introductions to industry partners. The half year saw our first two Portuguese spin outs join the portfolio.
An oversubscribed placing raised GBP2.33 million (net of expenses) for the Group, reflecting strong backing the Group enjoyed from existing and new investors.
Outlook
Our business continues to gather pace rapidly. The strong interest we are now seeing in our portfolio companies from a broad range and growing number of industry leaders is a clear indication our business model, with its strategic focus on identifying commercialisable IP and early engagement with commercial partners, is paying off. We are investing in our people and are confident that we are building on a strong base to deliver further progress during the second half of the financial year and beyond.
Neil Crabb
Chief Executive Officer
Results Summary
Financial assets at fair value through profit and loss at 31 December 2018 increased to GBP11,508,000 (30 June 2018: GBP9,060,000; 31 December 2017: GBP8,020,000). Total revenue over the first half increased by 83 per cent. to GBP2,176,000 (2017: GBP1,188,000) reflecting the higher investment revaluations (unrealised) of GBP1,983,000 (2017: GBP1,068,000) while revenue from services increased to GBP193,000 (2017: GBP120,000). The profit before tax increased by 138 per cent. to GBP1,247,000 (2017: GBP524,000) reflecting the higher investment revaluations, partially offset by the higher administrative expenses. Administrative expenses increased by 41 per cent. to GBP939,000 (2017: GBP667,000) primarily reflecting increased staff numbers, salaries and associated costs. Basic earnings per share was 3.18p (2017: 1.17p).
Cash balances stood at GBP2,528,000 as at 31 December 2018 (30 June 2018: GBP1,111,000; 31 December 2017: GBP1,849,000) following a placing in November 2018 which raised GBP2,333,000 net of expenses. Net assets per share as at 31 December 2018 were 38.8p (30 June 2018: 33.2p; 31 December 2017: 32.0p).
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the six months ended 31 December 2018
Hot Features
Premium
Six months Six months Year ended
ended 31 ended 31 30 June
December December 2018 (audited)
Notes 2018 (unaudited) 2017 (unaudited)
GBP'000 GBP'000 GBP'000
Revenue
Revenue from services 193 120 299
Other operating income
Unrealised profit on the revaluation
of
investments 7 1,983 1,068 2,064
Total revenue 2,176 1,188 2,363
Administrative expenses (939) (667) (1,465)
Profit from operations 1,237 521 898
Interest income on short-term
bank deposits 10 3 4
Profit before tax 1,247 524 902
Taxation 5 - (79) -
Profit and total comprehensive
income attributable to the equity
holders of the parent 1,247 445 902
================== =================== ================
Profit/ per share attributable
to the equity
holders of the parent
Basic earnings per share 6 3.18p 1.17p 2.36p
Diluted earnings per share 6 3.03p 1.13p 2.25p
All the Group's activities are classed as continuing and there were no comprehensive gains or losses in any period other than those included in the statement of comprehensive income.
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
At 31 December 2018
As at 31 As at 31 As at
December December 30 June
2018 (unaudited) 2017 (unaudited) 2018 (audited)
GBP'000 GBP'000 GBP'000
ASSETS Notes
Non-current assets
Tangible fixed assets 5 5 7
Goodwill 1,966 1,966 1,966
Financial assets at fair value
through profit and loss
Equity investments 7 11,403 8,020 9,060
Debt investments 7 105 -
Trade receivables and other
non-current assets 84 211 161
------------------- ------------------- ----------------
13,563 10,202 11,194
------------------- ------------------- ----------------
Current assets
Trade receivables and other
current assets 373 387 617
Cash and cash equivalents 2,528 1,849 1,111
------------------- ------------------- ----------------
2,901 2,236 1,728
Total assets 16,464 12,438 12,922
LIABILITIES
Non-current liabilities
Deferred taxation 5 - (79) -
------------------- ------------------- ----------------
- (79) -
------------------- ------------------- ----------------
Current liabilities
Trade and other payables (128) (126) (205)
------------------- ------------------- ----------------
(128) (126) (205)
------------------- ------------------- ----------------
Total liabilities (128) (205) (205)
------------------- ------------------- ----------------
Net assets 16,336 12,233 12,717
=================== =================== ================
EQUITY
Called up share capital 4,211 3,828 3,828
Share premium account 9,739 7,789 7,789
Reverse acquisition reserve (1,667) (1,667) (1,667)
Share based payment reserve 225 159 186
Retained earnings 3,828 2,124 2,581
------------------- ------------------- ----------------
Total equity 16,336 12,233 12,717
=================== =================== ================
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the six-months ended 31 December 2018
Share-
Share Reverse based Profit
Share premium acquisition payment and loss
capital account reserve reserve account Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
At 1st July 2017 3,828 7,789 (1,667) 130 1,679 11,759
Share-based payments - - - 29 - 29
Profit/comprehensive
income for the
period - - - - 445 445
At 31 December
2017 3,828 7,789 (1,667) 159 2,124 12,233
---------- ---------- -------------- --------- ----------- --------
Share-based payments - - - 27 - 27
Profit/comprehensive
income for the
period - - - - 457 457
---------- ---------- -------------- --------- ----------- --------
At 30 June 2018 3,828 7,789 (1,667) 186 2,581 12,717
---------- ---------- -------------- --------- ----------- --------
Issue of shares 383 1,950 - - - 2,333
Share-based payments - - - 39 - 39
Profit/comprehensive
income for the
period - - - - 1,247 1,247
At 31 December
2018 4,211 9,739 (1,667) 225 3,828 16,336
========== ========== ============== ========= =========== ========
CONSOLIDATED STATEMENT OF CASH FLOWS
For the six months ended 31 December 2018
Six months Six months Year ended
ended 31 ended 31 30 June
December December 2018 (audited)
2018 (unaudited) 2017 (unaudited) GBP'000
GBP'000 GBP'000
Cash flows from operating activities
Cash used in operations (458) (280) (970)
Taxation paid - - -
------------------ ------------------ ----------------
Net cash used in operating activities (458) (280) (970)
------------------ ------------------ ----------------
Cash flows from investing activities
Purchase of tangible fixed assets (2) (2) (7)
Purchase of financial assets at fair
value through profit and loss (466) (201) (245)
Interest received 10 3 4
------------------ ------------------ ----------------
Net cash used in investing activities (458) (200) (248)
------------------ ------------------
Cash flows from financing activities
Proceeds from issue of equity shares 2,488 - -
Costs of share issue (155) - -
------------------ ------------------ ----------------
Net cash generated from financing 2,333 - -
activities
------------------ ------------------ ----------------
Net increase/(decrease) in cash and
cash equivalents 1,417 (480) (1,218)
Cash and cash equivalents at beginning
of period 1,111 2,329 2,329
------------------ ------------------ ----------------
Cash and cash equivalents at end
of period 2,528 1,849 1,111
================== ================== ================
Cash used in operations
Profit before tax 1,247 524 902
Adjustments for:
Share-based payments 39 29 56
Depreciation 3 2 5
Interest received (10) (3) (4)
Fair value (gain) on financial assets
at fair value through profit or loss (1,983) (1,068) (2,064)
Changes in working capital:
Trade and other receivables 321 260 80
Trade and other payables (75) (24) 55
(458) (280) (970)
================== ================== ================
NOTES
1. General information
The Company is a limited liability company incorporated in England and with its registered office at 78 Cannon Street, London EC4N 6AF. The Company's main trading office is situated at 93 George Street, Edinburgh, EH2 3ES.
The Company is quoted on the AIM market.
This condensed consolidated interim financial information was approved and authorised for issue by a duly appointed and authorised committee of the Board of Directors on 26(th) March 2019.
This condensed interim financial information has not been audited or reviewed by the Company's auditor.
2. Basis of preparation
This condensed consolidated interim financial information for the six months ended 31 December 2018 has been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting". The condensed consolidated interim financial information should be read in conjunction with the annual financial statements for the year ended 30 June 2018, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU.
This condensed consolidated interim financial information does not constitute statutory accounts within the meaning of section 434 of the Companies Act 2006. The comparatives for the full year ended 30 June 2018 are not the Company's full statutory accounts for that year. A copy of the statutory accounts for that year has been delivered to the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain a statement under sections 498(2) or 498(3) of the Companies Act 2006.
3. Accounting policies
The accounting policies applied by the Group in these unaudited half year results are consistent with those applied in the annual financial statements for the year ended 30 June 2018 as described in the Group's Annual Report for that year and as available on our website www.frontierip.co.uk. No new standards that have become effective in the period have had a material effect on the Group's financial statements.
Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.
4. Segmental information
The chief operating decision-maker has been identified as the Group's board of directors. The board reviews the Group's internal reporting to assess performance and allocate resources. Currently the board considers that the Group has one operating activity, the commercialisation of university IP. The Group's revenue and profit/loss before taxation were derived almost entirely from its principal activities within the UK. Though the Group has partnerships and spin outs in Portugal the associated revenues and costs are currently immaterial and accordingly, no additional geographical disclosures are given.
5. Taxation
The taxation expense is recognised based on management's best estimate of the weighted average annual tax rate expected for the full financial year. The taxation expense for the six months to 31 December 2018 of nil (2017: GBP79,000) represents the recognition of a deferred tax liability on unrealised fair value gains less the recognition of available tax losses.
A deferred tax asset has not been recognised in respect of trading losses in view of the uncertainty as to the level of future taxable profits.
6. Earnings per share
The calculation of the basic earnings per share for the six months ended 31 December 2018 and 31 December 2017 and for the year ended 30 June 2018 is based on the earnings attributable to the shareholders of Frontier IP Group Plc in each period divided by the weighted average number of shares in issue during the period.
Basic earnings per share Weighted
Earnings average
attributable number Basic earnings
to shareholders of shares per share
GBP'000 Number Pence
Six months ended 31 December
2018 1,247 39,235,483 3.18
Six months ended 31 December
2017 445 38,278,520 1.17
Year ended 30 June 2018 902 38,278,520 2.36
Diluted earnings per share Weighted
Earnings average Diluted
attributable number earnings
to shareholders of shares per share
GBP'000 Number Pence
Six months ended 31 December
2018 1,247 41,109,539 3.03
Six months ended 31 December
2017 445 39,559,095 1.13
Year ended 30 June 2018 902 40,114,559 2.25
7. Financial Assets at Fair Value Through Profit and Loss
Financial assets at fair value through profit and loss comprise the following:
Unquoted Unquoted Limited Total
Equity Investments Debt Instruments Partnership
Interests
GBP'000 GBP'000 GBP'000 GBP'000
At 1(st) July 2017 6,729 - 22 6,751
Additions 200 - 4 204
Fair value increases 1,397 - - 1,397
Fair value decreases (325) - (7) (332)
-------------------- ------------------ ------------- --------
At 31(st) December
2017 8,001 - 19 8,020
-------------------- ------------------ ------------- --------
Additions
Fair value increases 41 - 3 44
Fair value increases 1,265 - 1,265
Fair value decreases (266) - (3) (269)
-------------------- ------------------ ------------- --------
At 30(th) June
2018 9,041 - 19 9,060
-------------------- ------------------ ------------- --------
Additions 360 105 1 466
Fair value increases 1,983 - - 1,983
Fair value decreases - - (1) (1)
-------------------- ------------------ ------------- --------
At 31(st) December
2018 11,384 105 19 11,508
==================== ================== ============= ========
The unquoted debt instruments totalling GBP105,000 reflect loans that have been made to certain portfolio companies in the period under review and which remain outstanding at 31 December 2018. The provision of such advances by Frontier IP to portfolio companies is to accelerate certain aspects of the commercialisation process for the portfolio companies and is line with the Group's capital efficient business model.
8. Copies of Half Yearly Report
Copies of the Half Yearly Report will be available on the Company's website, www.frontierip.co.uk, and on request from the Company's offices at 93 George Street, Edinburgh EH2 3ES no later than 29(th) March 2019.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IR DBGDXLSDBGCL
(END) Dow Jones Newswires
March 27, 2019 03:01 ET (07:01 GMT)
1 Year Frontier Ip Chart |
1 Month Frontier Ip Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
